Method and composition for treatment of headache using magnesium

• US 20010010827A1
• Filed: 02/07/2001
• Published: 08/02/2001
• Est. Priority Date: 04/08/1991
• Status: Abandoned Application

• Current Assignee: Alexander Mauskop, Bella T. Altura, Burton M. Altura
• Original Assignee: Alexander Mauskop, Bella T. Altura, Burton M. Altura
• Inventors: Altura, Bella T., Altura, Burton M., Mauskop, Alexander
• Application Number:
  US09/778,710
• Publication Number:
  US 20010010827A1
• Time in Patent Office: Days
• US Class Current: 424/677
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/28 Compounds containing heavy metals
• CPC Class Codes: A61K 33/06 Aluminium, calcium or magnesium; Compounds thereof , e.g. clay
• CPC Class Codes: A61K 33/42 Phosphorus; Compounds thereof
• CPC Class Codes: G01N 2800/04 Endocrine or metabolic disorders
• CPC Class Codes: G01N 2800/2807 Headache; Migraine
• CPC Class Codes: G01N 33/84 involving inorganic compounds or pH
• CPC Class Codes: Y10S 426/801 Pediatric
• CPC Class Codes: Y10T 436/106664 Blood serum or blood plasma standard or control
• CPC Class Codes: Y10T 436/109163 Inorganic standards or controls
• CPC Class Codes: Y10T 436/255 including use of a solid sorbent, semipermeable membrane, or liquid extraction

Abstract

A method for monitoring ionized Mg²⁺ concentrations and ionized Ca²⁺:Mg²⁺ ratios in a patient, useful in diagnosing and prognosing disease states including headache, cardiopulmonary bypass surgery, hypertension, abnormal pregnancy, head trauma, and fetal abnormalities is provided as well as a composition and a method of treating a patient with ionized Mg²⁺ or ionized Ca²⁺ and Mg²⁺. A method of treating headache is provided.

Claims

1. A method of diagnosis or prognosis of a headache in a patient, said headache capable of being diagnosed or prognosed by a method for determining ionized magnesium ion concentrations in biological samples, the method comprising:

a. collecting the biological sample under conditions which minimize or prevent exchange of gases between the biological sample and atmospheric air,

b. maintaining the biological sample under conditions which minimize or prevent exchange of gases between the biological sample and atmospheric air prior to measurement of ionized Mg²⁺,

c. measuring ionized Mg²⁺ concentrations, and

d. comparing the ionized Mg²⁺ concentration of the patient to a normal ionized Mg²⁺ concentration.

2. A method of

claim 1

wherein the normal ionized magnesium ion concentration is approximately 0.54 to 0.67 mM for the biological sample of whole blood, serum or plasma.

3. A composition for prevention or treatment of headache in an individual, the composition comprising as an active ingredient bioavailable magnesium, wherein a concentration of bioavailable magnesium in said composition is sufficient to prevent or treat the headache in the individual, said individual having an ionized magnesium deficiency prior to treatment.

4. A composition of

claim 3

wherein the concentration of elemental magnesium is at least 200 mg.

5. A composition of

claim 3

wherein the concentration of elemental magnesium is about 200 mg to about 400 mg.

6. A composition of

claim 3

wherein the magnesium is in the form of a highly water soluble, bioavailable, nontoxic salt.

7. A composition of

claim 3

wherein the magnesium is in the form of magnesium sulfate, MgSO₄.7H₂O, MgCl or MgCl.6H₂O.

8. A composition of

claim 6

wherein the magnesium salt is in a concentration of about 500 mg to about 5 gms.

9. A composition of

claim 7

wherein the magnesium sulfate is in a concentration of about 1 to about 3 grams.

10. Method of treating a headache in an individual comprising:

a. administration of bioavailable magnesium in an amount sufficient to inhibit at least one headache symptom in the individual.

11. The method of

claim 10

wherein the symptom is pain, aura, photophobia, nausea, unilateral pain, or phonophobia.

12. The method of

claim 10

wherein the administration is intravenous, subcutaneous, intramuscular, rectal, nasal, or aqueous oral administration.

13. The method of

claim 10

wherein the administration is provided intravenously over a two-to-fifteen-minute period.

14. The method of

claim 10

wherein the administration is more than one dose.

15. The method of

claim 10

wherein the magnesium is in the form of a highly water soluble, bioavailable, non-toxic salt.

16. The method of

claim 15

wherein the magnesium salt is magnesium sulfate. MgSO₄.7H₂O, MgCl, or MgCl.6H₂O.

17. The method of

claim 15

wherein about 500 mg to about 5 grams of the magnesium is administered.

18. The method of

claim 10

wherein the amount is sufficient to raise a serum ionized magnesium concentration in the patient to about 0.55 mM to about 0.67 mM.